News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Natera Launches Non-Invasive Prenatal Test Panorama™ With Best-in-Class Sensitivity, Specificity for Detection of Fetal Chromosomal Abnormalities


2/20/2013 10:46:49 AM

SAN CARLOS, Calif.--(BUSINESS WIRE)--Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that the company’s non-invasive prenatal screening test, Panorama™, will launch on March 1 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turner’s syndrome). In clinical validation studies, Panorama demonstrated a sensitivity of greater than 99% when detecting common chromosomal abnormalities such as trisomy 21, trisomy 18 and trisomy 13; and 92% when detecting monosomy X. In addition, Panorama demonstrated a specificity of 100% with no false positives for all the syndromes tested. The test uses fetal cell-free DNA found in maternal blood and works as early as nine weeks gestation. Panorama’s clinical validation data was presented live at the annual Society of Maternal Fetal Medicine Meeting on February 15, 2013.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES